医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan

2020年12月23日 PM12:00
このエントリーをはてなブックマークに追加


 

SANTA CLARA, Calif.

Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. The company also announced that it has registered its microarray scanner, SureScan Dx Scanner, as a Class I medical device in Japan, intended for use with the assay.

Based on Agilent’s proprietary microarray for comparative genomic hybridization (CGH), the GenetiSure Dx Postnatal Assay is a qualitative assay for the postnatal diagnosis of copy-number alterations (CNVs) and copy-neutral loss of heterozygosity (cnLOH) from genomic DNA (gDNA), obtained from the peripheral whole blood in patients who have been referred for chromosomal testing based on clinical presentation. The GenetiSure Dx Postnatal Assay is the result of a clinical validation utilizing 900 samples and brings CGH technology into a diagnostic setting in Japan. Available since 2017 as an in vitro diagnostic assay (IVD) in Europe and the United States, Japanese clinical geneticists can now have access to this assay to help identify a definitive genetic diagnosis for their patients.

“We are truly excited and humbled to bring the power of diagnostic microarray testing to the Japanese market. With clinically-proven performance and a track record of adoption in the U.S. and European Union, this presents a compelling option to patients, their families, and medical professionals to minimize the diagnostic odyssey often faced in clinical genetic testing settings,” said Kevin Meldrum, general manager and vice president of Agilent’s Genomics Solutions Division. “Agilent is in the process of preparing for the commercial launch of the assay in Japan, expected to occur in the first half of 2021.”

The assay is intended to be used on the SureScan Dx Microarray Scanner System and analyzed by CytoDx Software. This device is not intended to be used for standalone diagnostic purposes, pre-implantation or prenatal testing or screening, population screening, or for the detection of, or screening for, acquired or somatic genetic aberrations.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005553/en/

CONTACT

Naomi Goumillout

Agilent Technologies

+1.781.266.2819

naomi.goumillout@agilent.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists